Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9UHX1
UPID:
PUF60_HUMAN
Alternative names:
60 kDa poly(U)-binding-splicing factor; FUSE-binding protein-interacting repressor; Ro-binding protein 1; Siah-binding protein 1
Alternative UPACC:
Q9UHX1; A8K8K8; Q969E7; Q96D94; Q96H63; Q99628; Q9NZA0; Q9UJY7
Background:
Poly(U)-binding-splicing factor PUF60, also known as 60 kDa poly(U)-binding-splicing factor, plays a pivotal role in nuclear processes including pre-mRNA splicing, apoptosis, and transcription regulation. It influences MYC transcription, acts as a transcriptional repressor, and is involved in DNA binding at active promoter regions. PUF60's interaction with FUBP1 and its involvement in alternative splicing of mRNAs highlight its multifaceted biological functions.
Therapeutic significance:
PUF60's association with Verheij syndrome, characterized by growth retardation and developmental delays, underscores its clinical relevance. Understanding the role of Poly(U)-binding-splicing factor PUF60 could open doors to potential therapeutic strategies for managing this syndrome and possibly other related genetic disorders.